Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does USTEKINUMAB-STBA Cause Intentional product use issue? 46 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 46 reports of Intentional product use issue have been filed in association with USTEKINUMAB-STBA. This represents 25.0% of all adverse event reports for USTEKINUMAB-STBA.

46
Reports of Intentional product use issue with USTEKINUMAB-STBA
25.0%
of all USTEKINUMAB-STBA reports
2
Deaths
6
Hospitalizations

How Dangerous Is Intentional product use issue From USTEKINUMAB-STBA?

Of the 46 reports, 2 (4.3%) resulted in death, 6 (13.0%) required hospitalization, and 1 (2.2%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB-STBA. However, 46 reports have been filed with the FAERS database.

What Other Side Effects Does USTEKINUMAB-STBA Cause?

Off label use (43) Intentional dose omission (21) Crohn's disease (20) Death (15) Haematochezia (13) Condition aggravated (12) Diarrhoea (10) Colitis ulcerative (8) Psoriasis (8) Abdominal pain (6)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which USTEKINUMAB-STBA Alternatives Have Lower Intentional product use issue Risk?

USTEKINUMAB-STBA vs VADADUSTAT USTEKINUMAB-STBA vs VALACYCLOVIR USTEKINUMAB-STBA vs VALBENAZINE USTEKINUMAB-STBA vs VALBENAZINE DITOSYLATE USTEKINUMAB-STBA vs VALDECOXIB

Related Pages

USTEKINUMAB-STBA Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue USTEKINUMAB-STBA Demographics